| Literature DB >> 18673553 |
Roberta Bacchiocchi1, Corrado Rubini, Elisa Pierpaoli, Giulia Borghetti, Pasquale Procacci, Pier Francesco Nocini, Andrea Santarelli, Romina Rocchetti, Domenico Ciavarella, Lorenzo Lo Muzio, Francesca Fazioli.
Abstract
BACKGROUND: Oral squamous cell carcinoma (OSCC) represents the most common oral malignancy. Despite recent advances in therapy, up to 50% of the cases have relapse and/or metastasis. There is therefore a strong need for the identification of new biological markers able to predict the clinical behaviour of these lesions in order to improve quality of life and overall survival. Among tumour progression biomarkers, already known for their involvement in other neoplasia, a crucial role is ascribed to the urokinase-type plasminogen activator receptor (uPAR), which plays a multiple role in extracellular proteolysis, cell migration and tissue remodelling not only as a receptor for the zymogen pro-uPA but also as a component for cell adhesion and as a chemoattractant. The purpose of this study was to gain information on the expression of uPAR in OSCC and to verify whether this molecule can have a role as a prognostic/predictive marker for this neoplasia.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18673553 PMCID: PMC2527016 DOI: 10.1186/1471-2407-8-220
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Patient Characteristics
| 1 | 77 | G1 | 41 | 17 | 8 | 11 |
| 2 | 68 | G2 | 28 | 13 | 8 | 19 |
| 3 | 44 | G3 | 10 | 9 | 9 | 16 |
| 4 | 8 | normal mucosa | ||||
Figure 1uPAR expression in OSCC. A: Strong cytoplasmic positivity of neoplastic epithelial cells in poorly differentiated OSCC (G3) (× 250). B: Weak cytoplasmic positivity of epithelial cells of invasive front in moderately differentiated OSCC (G2) (× 200). C: Focal strong positivity in stromal and inflammatory peritumoral cells in moderately differentiated OSCC (G2) (× 160). D: Negativity of an adjacent section incubated with an isotype-matched monoclonal control antibody (× 400).
Statistical analysis of uPAR expression and associated clinicopathological findings in OSCCs
| Cases | 189 | 74 (39.1) | ||||||||
| Age | ||||||||||
| < 65 years | 78 | 25 (32) | No | 39 | 19.8 | 14 | No | |||
| > 65 years | 111 | 49 (44) | 0.0989° | 55.5 | 9.192 | 6.5 | 0.0854 | |||
| Sex | ||||||||||
| Male | 143 | 56 (39.1) | No | 71.5 | 21.92 | 15.5 | No | |||
| Female | 46 | 18 (39.1) | 1.0000° | 23 | 7.071 | 5 | 0.7103 | |||
| Grading | ||||||||||
| G1 | 77 | 16 (20.8) | Yes | 3.052 | 8.515 | 0.9703 | Yes | G1 vs G2 | -16,14 | No |
| G2 | 68 | 27 (39.7) | < 0.0001 | 5.103 | 12.09 | 1.466 | < 0.0001* | G1 vs G3 | -50,00 | Yes |
| G3 | 44 | 31 (70.4) | 14.77 | 20.52 | 3.094 | G2 vs G3 | -33,87 | Yes | ||
| Size | ||||||||||
| < 1.5 cm | 48 | 17 (35.4) | No | 3.958 | 8.124 | 1.173 | No | |||
| > 1.5 cm | 141 | 57 (40.4) | 0.6092° | 7.157 | 15.28 | 1.292 | 0.4607 | |||
| Recurrence | ||||||||||
| Positive | 85 | 37 (43.5) | No | 42.5 | 7.778 | 5.5 | No | |||
| Negative | 104 | 37 (35.5) | 0.296° | 52 | 21.21 | 15 | 0.5866 | |||
| Staging | ||||||||||
| I | 79 | 25 (31.6) | 4.873 | 13.47 | 1.516 | I vs II | -10,44 | No | ||
| II | 39 | 16 (41) | No | 6.231 | 11.45 | 1.833 | No | I vs III | -3,138 | No |
| III | 25 | 9 (36) | 0.2307 | 3.760 | 7.055 | 1.411 | 0.0725* | I vs IV | -22,96 | No |
| IV | 46 | 24 (52) | 10.39 | 17.78 | 2.621 | II vs III | 7,302 | No | ||
| II vs IV | -12,52 | No | ||||||||
| III vs IV | -19,82 | No | ||||||||
°Fisher's exact test
* Kruskal-Wallis test
Figure 2Prognostic value of uPAR expression. Kaplan-Meier curves for OSCC patients correlating uPAR expression and overall survival (A) (p = 0.0053), survival in grade 1 (B) (p = 0.0447), grade 2 (C) (p = 0.3427) and grade 3 (D) (p = 0.7143) tumours. Dotted line, uPAR negative cases ; continuous line, uPAR positive cases.